UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Clinical cancer research, 2016-02, Vol.22 (4), p.868-876

2016

Volltextzugriff (PDF)

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

The lancet oncology, 2012-11, Vol.13 (11), p.1133-1140

2012

Volltextzugriff (PDF)

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Haematologica (Roma), 2016-05, Vol.101 (5), p.e185

2016

Volltextzugriff (PDF)

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor

Proceedings of the National Academy of Sciences - PNAS, 2015-08, Vol.112 (34), p.10732-10737

2015

Volltextzugriff (PDF)

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Molecular cancer therapeutics, 2017-10, Vol.16 (10), p.2315-2323

2017

Volltextzugriff (PDF)

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

Clinical cancer research, 2009-12, Vol.15 (23), p.7368-7374

2009

Volltextzugriff (PDF)

Long Non-coding RNAs and their Role in Metastasis

Cancer genomics & proteomics, 2017-05, Vol.14 (3), p.143-160

2017

Volltextzugriff (PDF)

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

Molecular cancer therapeutics, 2009-09, Vol.8 (9), p.2517-2525

2009

Volltextzugriff (PDF)

Mechanisms and Targets Involved in Dissemination of Ovarian Cancer

Cancer genomics & proteomics, 2016-11, Vol.13 (6), p.407-423

2016

Volltextzugriff (PDF)

The Multiple Roles of Exosomes in Metastasis

Cancer genomics & proteomics, 2017-02, Vol.14 (1), p.1-15

2017

Volltextzugriff (PDF)

Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas

Applied immunohistochemistry & molecular morphology, 2011-01, Vol.19 (1), p.54

2011

Volltextzugriff (PDF)

Molecular Mechanisms of Bone Metastasis

Cancer genomics & proteomics, 2016-01, Vol.13 (1), p.1-12

2016

Volltextzugriff (PDF)

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors

Clinical cancer research, 2012-09, Vol.18 (17), p.4806-4819

2012

Volltextzugriff (PDF)

Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention

Cancer genomics & proteomics, 2016-07, Vol.13 (4), p.245-258

2016

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-09, Vol.18 (17), p.4794-4805

2012

Volltextzugriff (PDF)

MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia

British journal of haematology, 2015-11, Vol.171 (3), p.432-435

2015

Volltextzugriff (PDF)

Loss of diphthamide pre-activates NF-[kappa]B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor

Proceedings of the National Academy of Sciences - PNAS, 2015-08, Vol.112 (34), p.10732

2015

Volltextzugriff (PDF)

Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia

Clinical cancer research, 2015-10, Vol.22 (4), p.868-876

2015

Volltextzugriff (PDF)

MDM 2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia

British journal of haematology, 2015-11, Vol.171 (3), p.432-435

2015

Volltextzugriff (PDF)

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression

Journal of clinical pharmacology, 2010-12, Vol.50 (12), p.1397-1405

2010

Volltextzugriff (PDF)

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of R05126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Clinical cancer research, 2012, Vol.18 (17), p.4806-4819

2012

Volltextzugriff (PDF)

Identification of gene signatures for invasive colorectal tumor cells

Cancer detection and prevention, 2007-01, Vol.31 (4), p.282-295

2007

Volltextzugriff (PDF)

Methoden der Genübertragung

Molekular- und Zellbiologische Grundlagen, p.197-241

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(18)
Science & Technology
(18)
Life Sciences & Biomedicine
(17)
Oncology
(14)
Female
(11)
Male
(10)
Adult
(8)
Middle Aged
(8)
Aged
(7)
Neoplasm Metastasis
(6)
Animals
(5)
Dose-Response Relationship, Drug
(5)
Genetics & Heredity
(5)
Review
(5)
Neoplasms - Pathology
(4)
Proto-Oncogene Proteins C-Mdm2 - Metabolism
(4)
Tumors
(4)
Administration, Oral
(3)
Antineoplastic Agents
(3)
Biological And Medical Sciences
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

Long Non-coding RNAs and their Role in Metastasis

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

Mechanisms and Targets Involved in Dissemination of Ovarian Cancer

The Multiple Roles of Exosomes in Metastasis

Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas

Molecular Mechanisms of Bone Metastasis

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors

Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia

Loss of diphthamide pre-activates NF-[kappa]B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia

MDM 2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of R05126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Identification of gene signatures for invasive colorectal tumor cells

Methoden der Genübertragung

Suchergebnisse filtern